149 results on '"Humar, B."'
Search Results
2. Phase Ib dose-escalation study of the hypoxia-modifier myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
- Author
-
Schneider, M, primary, Linecker, M, additional, Fritsch, R, additional, Mühlematter, U, additional, Stocker, D, additional, Pestalozzi, B, additional, Samaras, P, additional, Jetter, A, additional, Kron, P, additional, Petrowsky, H, additional, Nicolau, C, additional, Lehn, J-M, additional, Humar, B, additional, Graf, R, additional, Clavien, P-A, additional, and Limani, P, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Remote ischemic preconditioning is protective in complex liver surgery of the elderly: an experimental study
- Author
-
Limani, P., Linecker, M., Oberkofler, C., Humar, B., Graf, R., and Clavien, P.-A.
- Published
- 2015
4. Inositol trispyrophosphate (ITPP) and its anti-hypoxic potential in colorectal metastases of the liver
- Author
-
Limani, P., Linecker, M., Kachaylo, E., Tschuor, C., Schlegel, A., Jang, J.-H., Georgioupolou, S., Lehn, J.-M., Graf, R., Humar, B., and Clavien, P.-A.
- Published
- 2015
5. ALPPS: From human to mice highlighting accelerated and novel mechanisms of liver regeneration
- Author
-
Schlegel, A., Lesurtel, M., Melloul, E., Limani, P., Tschuor, C., Graf, R., Humar, B., and Clavien, P.-A.
- Published
- 2015
6. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
- Author
-
Graziano, F, Ruzzo, A, Canestrari, E, Loupakis, F, Santini, D, Rulli, E, Humar, B, Galluccio, N, Bisonni, R, Floriani, I, Maltese, P, Falcone, A, Tonini, G, Catalano, V, Fontana, A, Giustini, L, Masi, G, Vincenzi, B, Alessandroni, P, and Magnani, M
- Published
- 2009
- Full Text
- View/download PDF
7. Hereditary diffuse gastric cancer: updated clinical practice guidelines
- Author
-
Blair, V.R., McLeod, M., Carneiro, F., Coit, D.G., D'Addario, J.L., Dieren, J.M. van, Harris, K.L., Hoogerbrugge, N., Oliveira, C. de, Post, R.S. van der, Arnold, J., Benusiglio, P.R., Bisseling, T.M., Boussioutas, A., Cats, A., Charlton, A., Schreiber, K.E., Davis, J.L., Pietro, M.D., Fitzgerald, R.C., Ford, J.M., Gamet, K., Gullo, I., Hardwick, R.H., Huntsman, D.G., Kaurah, P., Kupfer, S.S., Latchford, A., Mansfield, P.F., Nakajima, T., Parry, S., Rossaak, J., Sugimura, H., Svrcek, M., Tischkowitz, M., Ushijima, T., Yamada, H., Yang, H.Keri, Claydon, A., Figueiredo, J., Paringatai, K., Seruca, R., Bougen-Zhukov, N., Brew, T., Busija, S., Carneiro, P., DeGregorio, L., Fisher, H., Gardner, E., Godwin, T.D., Holm, K.N., Humar, B., Lintott, C.J., Monroe, E.C., Muller, M.D., Norero, E., Nouri, Y., Paredes, J., Sanches, J.M., Schulpen, E., Ribeiro, A.S., Sporle, A., Whitworth, J., Zhang, L., Reeve, A.E., Guilford, P., Blair, V.R., McLeod, M., Carneiro, F., Coit, D.G., D'Addario, J.L., Dieren, J.M. van, Harris, K.L., Hoogerbrugge, N., Oliveira, C. de, Post, R.S. van der, Arnold, J., Benusiglio, P.R., Bisseling, T.M., Boussioutas, A., Cats, A., Charlton, A., Schreiber, K.E., Davis, J.L., Pietro, M.D., Fitzgerald, R.C., Ford, J.M., Gamet, K., Gullo, I., Hardwick, R.H., Huntsman, D.G., Kaurah, P., Kupfer, S.S., Latchford, A., Mansfield, P.F., Nakajima, T., Parry, S., Rossaak, J., Sugimura, H., Svrcek, M., Tischkowitz, M., Ushijima, T., Yamada, H., Yang, H.Keri, Claydon, A., Figueiredo, J., Paringatai, K., Seruca, R., Bougen-Zhukov, N., Brew, T., Busija, S., Carneiro, P., DeGregorio, L., Fisher, H., Gardner, E., Godwin, T.D., Holm, K.N., Humar, B., Lintott, C.J., Monroe, E.C., Muller, M.D., Norero, E., Nouri, Y., Paredes, J., Sanches, J.M., Schulpen, E., Ribeiro, A.S., Sporle, A., Whitworth, J., Zhang, L., Reeve, A.E., and Guilford, P.
- Abstract
Contains fulltext : 225261.pdf (Publisher’s version ) (Closed access), Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour suppressor gene CDH1, although pathogenic variants in CTNNA1 occur in a minority of families with HDGC. In this Policy Review, we present updated clinical practice guidelines for HDGC from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in gastric cancer risk between families with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients. To redress the balance between the accessibility, cost, and acceptance of genetic testing and the increased identification of pathogenic variant carriers, the HDGC genetic testing criteria have been relaxed, mainly through less restrictive age limits. Prophylactic total gastrectomy remains the recommended option for gastric cancer risk management in pathogenic CDH1 variant carriers. However, there is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely offered to patients who wish to postpone surgery, or to those whose risk of developing gastric cancer is not well defined.
- Published
- 2020
8. Hereditary diffuse gastric cancer: updated clinical practice guidelines
- Author
-
Blair, VR, McLeod, M, Carneiro, F, Coit, DG, D'Addario, JL, van Dieren, JM, Harris, KL, Hoogerbrugge, N, Oliveira, C, van der Post, RS, Arnold, J, Benusiglio, PR, Bisseling, TM, Boussioutas, A, Cats, A, Charlton, A, Schreiber, KEC, Davis, JL, di Pietro, M, Fitzgerald, RC, Ford, JM, Gamet, K, Gullo, I, Hardwick, RH, Huntsman, DG, Kaurah, P, Kupfer, SS, Latchford, A, Mansfield, PF, Nakajima, T, Parry, S, Rossaak, J, Sugimura, H, Svrcek, M, Tischkowitz, M, Ushijima, T, Yamada, H, Yang, H-K, Claydon, A, Figueiredo, J, Paringatai, K, Seruca, R, Bougen-Zhukov, N, Brew, T, Busija, S, Carneiro, P, DeGregorio, L, Fisher, H, Gardner, E, Godwin, TD, Holm, KN, Humar, B, Lintott, CJ, Monroe, EC, Muller, MD, Norero, E, Nouri, Y, Paredes, J, Sanches, JM, Schulpen, E, Ribeiro, AS, Sporle, A, Whitworth, J, Zhang, L, Reeve, AE, Guilford, P, Blair, VR, McLeod, M, Carneiro, F, Coit, DG, D'Addario, JL, van Dieren, JM, Harris, KL, Hoogerbrugge, N, Oliveira, C, van der Post, RS, Arnold, J, Benusiglio, PR, Bisseling, TM, Boussioutas, A, Cats, A, Charlton, A, Schreiber, KEC, Davis, JL, di Pietro, M, Fitzgerald, RC, Ford, JM, Gamet, K, Gullo, I, Hardwick, RH, Huntsman, DG, Kaurah, P, Kupfer, SS, Latchford, A, Mansfield, PF, Nakajima, T, Parry, S, Rossaak, J, Sugimura, H, Svrcek, M, Tischkowitz, M, Ushijima, T, Yamada, H, Yang, H-K, Claydon, A, Figueiredo, J, Paringatai, K, Seruca, R, Bougen-Zhukov, N, Brew, T, Busija, S, Carneiro, P, DeGregorio, L, Fisher, H, Gardner, E, Godwin, TD, Holm, KN, Humar, B, Lintott, CJ, Monroe, EC, Muller, MD, Norero, E, Nouri, Y, Paredes, J, Sanches, JM, Schulpen, E, Ribeiro, AS, Sporle, A, Whitworth, J, Zhang, L, Reeve, AE, and Guilford, P
- Abstract
Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour suppressor gene CDH1, although pathogenic variants in CTNNA1 occur in a minority of families with HDGC. In this Policy Review, we present updated clinical practice guidelines for HDGC from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in gastric cancer risk between families with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients. To redress the balance between the accessibility, cost, and acceptance of genetic testing and the increased identification of pathogenic variant carriers, the HDGC genetic testing criteria have been relaxed, mainly through less restrictive age limits. Prophylactic total gastrectomy remains the recommended option for gastric cancer risk management in pathogenic CDH1 variant carriers. However, there is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely offered to patients who wish to postpone surgery, or to those whose risk of developing gastric cancer is not well defined.
- Published
- 2020
9. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype
- Author
-
Ruzzo, A., Graziano, F., Pizzagalli, F., Santini, D., Battistelli, V., Panunzi, S., Canestrari, E., Catalano, V., Humar, B., Ficarelli, R., Bearzi, I., Cascinu, S., Naldi, N., Testa, E., and Magnani, M.
- Published
- 2005
- Full Text
- View/download PDF
10. Identification of Seven Novel Germline Mutations in the Human E-Cadherin (CDH1) Gene
- Author
-
More, H., Humar, B., Weber, W., Ward, R., Christian, A., Lintott, C., Graziano, F., Ruzzo, A-M., Acosta, E., Boman, B., Harlan, M., Ferreira, P., Seruca, R., Suriano, G., and Guilford, P.
- Published
- 2007
- Full Text
- View/download PDF
11. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice
- Author
-
Graziano, F., Humar, B., and Guilford, P.
- Published
- 2003
12. Cell cycle dependent DNA break increase in ataxia telangiectasia lymphoblasts after radiation exposure
- Author
-
Humar, B, Müller, H, and Scott, R J
- Published
- 2001
13. Exercise improves outcomes of surgery on fatty liver and can be substituted through AMPK activation - an experimental study
- Author
-
Linecker, M., primary, Limani, P., additional, Frick, L., additional, Schneider, M., additional, Kambakamba, P., additional, Kron, P., additional, Tschuor, C., additional, Calo, N., additional, Foti, M., additional, Dufour, J.-F., additional, Graf, R., additional, Humar, B., additional, and Clavien, P.-A., additional
- Published
- 2019
- Full Text
- View/download PDF
14. First evidence of antitumor activity of ITPP, a novel hypoxia-modifier: Results of a phase Ib trial
- Author
-
Schneider, M.A., primary, Limani, P., additional, Linecker, M., additional, Kron, P., additional, Petrosky, H., additional, Pestalozzi, B.C., additional, Jetter, A., additional, Graf, R., additional, Humar, B., additional, Lehn, J.-M., additional, and Clavien, P.-A., additional
- Published
- 2018
- Full Text
- View/download PDF
15. Sewed revascularization for arterialized liver transplantation in mice
- Author
-
Humar B Raptis DA Weber A Graf R Clavien PA Tian Y
- Subjects
surgical procedures, operative - Abstract
BACKGROUND: Mouse models of liver transplantation are powerful tools for biomedical research. The cuff method is currently the most popular approach for revascularization of mouse liver grafts as it is relatively easy to perform hence reducing the anhepatic time. However the use of cuffs may induce a tissue reaction causing chronic obstruction of anastomosed vessels leading to portal hypertension. Here we applied the suture technique for arterialized liver transplantation in mice. MATERIALS AND METHODS: Liver transplantation was performed on 14 pairs of C57BL/6 mice. All hepatic vessels were anastomosed by sewing. The bile duct was connected with a stent. The liver grafts were harvested for histology on day 30 after surgery. Serum aspartate transaminase alkaline phosphatase and bilirubin were measured at d 3 7 and 30 after implantation. RESULTS: With a mean anhepatic time of 25.78 ± 3 min the survival rate was 86 (n = 14) at 30 d following surgery. During this period no significant liver injury was observed as assessed by serum markers and histology. Survival remained stable when grafts were exposed to 6 h cold ischemia prior to implantation. Vessel examination at the end of the studied period revealed an intact patency and a lack of collateral vessel growth. CONCLUSION: Arterialized liver transplantation with sewed revascularization in mice is technically feasible. Both sewing and arterialization seem to be important factors promoting the survival of mouse recipients. The mouse model of suture arterialized orthotopic liver transplantation provides a novel tool for modern transplantation research and might be particularly suited for studies requiring longer term survival of recipients.
- Published
- 2013
- Full Text
- View/download PDF
16. Antihypoxic potentiation of standard therapy for experimental colorectal liver metastasis through myo-inositol trispyrophosphate
- Author
-
Limani, P, Linecker, M, Kachaylo, E, Tschuor, C, Kron, P, Schlegel, A, Ungethuem, U, Jang, J H, Georgiopoulou, S, Claude Nicolau, C, Lehn, J-M, Graf, R, Humar, B, Clavien, P-A, Limani, P, Linecker, M, Kachaylo, E, Tschuor, C, Kron, P, Schlegel, A, Ungethuem, U, Jang, J H, Georgiopoulou, S, Claude Nicolau, C, Lehn, J-M, Graf, R, Humar, B, and Clavien, P-A
- Abstract
PURPOSE: Tumor hypoxia activates hypoxia-inducible factors (Hifs), which induce a range of malignant changes including vascular abnormalities. Here, we determine whether inhibition of the hypoxic tumor response through myo-inositol trispyrophosphate (ITPP), a compound with antihypoxic properties, is able to cause prolonged vascular normalization that can be exploited to improve standard-of-care treatment. EXPERIMENTAL DESIGN: We tested ITPP on two syngeneic orthotopic mouse models of lethal colorectal cancer liver metastasis. Tumors were monitored by MRI and analyzed for the hypoxic response and their malignant potential. A Hif activator and in vitro assays were used to define the working mode of ITPP. Hypoxic response and vasculature were re-evaluated 4 weeks after treatment. Finally, we determined survival following ITPP monotherapy, FOLFOX monotherapy, FOLFOX plus Vegf antibody, and FOLFOX plus ITPP, both overlapping and sequential. RESULTS: ITPP reduced tumor load, efficiently inhibited the hypoxic response, and improved survival. These effects were lost when mice were pretreated with a Hif activator. Its immediate effects on the hypoxic response, including an apparent normalization of tumor vasculature, persisted for at least 4 weeks after treatment cessation. Compared with FOLFOX alone, Vegf antibody combined with FOLFOX prolonged survival by <30%, whereas ITPP combined with FOLFOX extended survival by >140%, regardless of whether FOLFOX was given in overlap or after ITPP exposure. CONCLUSIONS: Our findings reveal a truly antihypoxic mechanism for ITPP and demonstrate the capacity of this nontoxic compound to potentiate the efficacy of existing anticancer treatment in a way amenable to clinical translation. Clin Cancer Res; 22(23); 5887-97.
- Published
- 2016
17. 101P - First evidence of antitumor activity of ITPP, a novel hypoxia-modifier: Results of a phase Ib trial
- Author
-
Schneider, M.A., Limani, P., Linecker, M., Kron, P., Petrosky, H., Pestalozzi, B.C., Jetter, A., Graf, R., Humar, B., Lehn, J.-M., and Clavien, P.-A.
- Published
- 2018
- Full Text
- View/download PDF
18. Molecular Mechanisms Underlying the Unprecedented Liver Regeneration Induced by Alpps Surgery
- Author
-
Langiewicz, M., primary, Schlegel, A., additional, Humar, B., additional, Graf, R., additional, and Clavien, P.-A., additional
- Published
- 2016
- Full Text
- View/download PDF
19. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
- Author
-
Post, R.S. van der, Vogelaar, I.P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., Caldas, C., Schreiber, K.E., Hardwick, R.H., Ausems, M.G.E.M., Bardram, L., Benusiglio, P.R., Bisseling, T.M., Blair, V., Bleiker, E., Boussioutas, A., Cats, A., Coit, D., DeGregorio, L., Figueiredo, J., Ford, J.M., Heijkoop, E., Hermens, R.P., Humar, B., Kaurah, P., Keller, G., Lai, J., Ligtenberg, M.J., O'Donovan, M., Oliveira, C., Pinheiro, H., Ragunath, K., Rasenberg, E., Richardson, S., Roviello, F., Schackert, H., Seruca, R., Taylor, A., Huurne, A. Ter, Tischkowitz, M., Joe, S.T., Dijck, B. van, Grieken, N.C. van, Hillegersberg, R. van, Sandick, J.W. van, Vehof, M.E.J., Krieken, J.H.J.M. van, Fitzgerald, R.C., Post, R.S. van der, Vogelaar, I.P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., Caldas, C., Schreiber, K.E., Hardwick, R.H., Ausems, M.G.E.M., Bardram, L., Benusiglio, P.R., Bisseling, T.M., Blair, V., Bleiker, E., Boussioutas, A., Cats, A., Coit, D., DeGregorio, L., Figueiredo, J., Ford, J.M., Heijkoop, E., Hermens, R.P., Humar, B., Kaurah, P., Keller, G., Lai, J., Ligtenberg, M.J., O'Donovan, M., Oliveira, C., Pinheiro, H., Ragunath, K., Rasenberg, E., Richardson, S., Roviello, F., Schackert, H., Seruca, R., Taylor, A., Huurne, A. Ter, Tischkowitz, M., Joe, S.T., Dijck, B. van, Grieken, N.C. van, Hillegersberg, R. van, Sandick, J.W. van, Vehof, M.E.J., Krieken, J.H.J.M. van, and Fitzgerald, R.C.
- Abstract
Contains fulltext : 152968.pdf (publisher's version ) (Open Access), Germline CDH1 mutations confer a high lifetime risk of developing diffuse gastric (DGC) and lobular breast cancer (LBC). A multidisciplinary workshop was organised to discuss genetic testing, surgery, surveillance strategies, pathology reporting and the patient's perspective on multiple aspects, including diet post gastrectomy. The updated guidelines include revised CDH1 testing criteria (taking into account first-degree and second-degree relatives): (1) families with two or more patients with gastric cancer at any age, one confirmed DGC; (2) individuals with DGC before the age of 40 and (3) families with diagnoses of both DGC and LBC (one diagnosis before the age of 50). Additionally, CDH1 testing could be considered in patients with bilateral or familial LBC before the age of 50, patients with DGC and cleft lip/palate, and those with precursor lesions for signet ring cell carcinoma. Given the high mortality associated with invasive disease, prophylactic total gastrectomy at a centre of expertise is advised for individuals with pathogenic CDH1 mutations. Breast cancer surveillance with annual breast MRI starting at age 30 for women with a CDH1 mutation is recommended. Standardised endoscopic surveillance in experienced centres is recommended for those opting not to have gastrectomy at the current time, those with CDH1 variants of uncertain significance and those that fulfil hereditary DGC criteria without germline CDH1 mutations. Expert histopathological confirmation of (early) signet ring cell carcinoma is recommended. The impact of gastrectomy and mastectomy should not be underestimated; these can have severe consequences on a psychological, physiological and metabolic level. Nutritional problems should be carefully monitored.
- Published
- 2015
20. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
- Author
-
van der Post, RS, Vogelaar, IP, Carneiro, F, Guilford, P, Huntsman, D, Hoogerbrugge, N, Caldas, C, Schreiber, KEC, Hardwick, RH, Ausems, MGEM, Bardram, L, Benusiglio, PR, Bisseling, TM, Blair, V, Bleiker, E, Boussioutas, A, Cats, A, Coit, D, DeGregorio, L, Figueiredo, J, Ford, JM, Heijkoop, E, Hermens, R, Humar, B, Kaurah, P, Keller, G, Lai, J, Ligtenberg, MJL, O'Donovan, M, Oliveira, C, Pinheiro, H, Ragunath, K, Rasenberg, E, Richardson, S, Roviello, F, Schackert, H, Seruca, R, Taylor, A, ter Huurne, A, Tischkowitz, M, Joe, STA, van Dijck, B, van Grieken, NCT, van Hillegersberg, R, van Sandick, JW, Vehof, R, van Krieken, JH, Fitzgerald, RC, van der Post, RS, Vogelaar, IP, Carneiro, F, Guilford, P, Huntsman, D, Hoogerbrugge, N, Caldas, C, Schreiber, KEC, Hardwick, RH, Ausems, MGEM, Bardram, L, Benusiglio, PR, Bisseling, TM, Blair, V, Bleiker, E, Boussioutas, A, Cats, A, Coit, D, DeGregorio, L, Figueiredo, J, Ford, JM, Heijkoop, E, Hermens, R, Humar, B, Kaurah, P, Keller, G, Lai, J, Ligtenberg, MJL, O'Donovan, M, Oliveira, C, Pinheiro, H, Ragunath, K, Rasenberg, E, Richardson, S, Roviello, F, Schackert, H, Seruca, R, Taylor, A, ter Huurne, A, Tischkowitz, M, Joe, STA, van Dijck, B, van Grieken, NCT, van Hillegersberg, R, van Sandick, JW, Vehof, R, van Krieken, JH, and Fitzgerald, RC
- Abstract
Germline CDH1 mutations confer a high lifetime risk of developing diffuse gastric (DGC) and lobular breast cancer (LBC). A multidisciplinary workshop was organised to discuss genetic testing, surgery, surveillance strategies, pathology reporting and the patient's perspective on multiple aspects, including diet post gastrectomy. The updated guidelines include revised CDH1 testing criteria (taking into account first-degree and second-degree relatives): (1) families with two or more patients with gastric cancer at any age, one confirmed DGC; (2) individuals with DGC before the age of 40 and (3) families with diagnoses of both DGC and LBC (one diagnosis before the age of 50). Additionally, CDH1 testing could be considered in patients with bilateral or familial LBC before the age of 50, patients with DGC and cleft lip/palate, and those with precursor lesions for signet ring cell carcinoma. Given the high mortality associated with invasive disease, prophylactic total gastrectomy at a centre of expertise is advised for individuals with pathogenic CDH1 mutations. Breast cancer surveillance with annual breast MRI starting at age 30 for women with a CDH1 mutation is recommended. Standardised endoscopic surveillance in experienced centres is recommended for those opting not to have gastrectomy at the current time, those with CDH1 variants of uncertain significance and those that fulfil hereditary DGC criteria without germline CDH1 mutations. Expert histopathological confirmation of (early) signet ring cell carcinoma is recommended. The impact of gastrectomy and mastectomy should not be underestimated; these can have severe consequences on a psychological, physiological and metabolic level. Nutritional problems should be carefully monitored.
- Published
- 2015
21. P0408 : The regulation of liver volume gain and regeneration-associated steatosis through Pten
- Author
-
Kachaylo, E., primary, Tschuor, C., additional, Linecker, M., additional, Limani, P., additional, Foti, M., additional, Graf, R., additional, Humar, B., additional, and Clavien, P.-A., additional
- Published
- 2015
- Full Text
- View/download PDF
22. P1333 : A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven™) on outcome after major liver resection
- Author
-
Linecker, M., primary, Limani, P., additional, Botea, F., additional, Popescu, I., additional, Alikhanov, R., additional, Efanov, M., additional, Khatkov, I., additional, Raptis, D., additional, Tschuor, C., additional, Beck Schimmer, B., additional, Bonvini, J., additional, Wirsching, A., additional, Kron, P., additional, Slankamenac, K., additional, Humar, B., additional, Graf, R., additional, Petrowsky, H., additional, and Clavien, P.A., additional
- Published
- 2015
- Full Text
- View/download PDF
23. Peer-reveiwed study protocol: A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven) on outcome after major liver resection
- Author
-
Linecker M Limani P Humar B Clavien PA
- Abstract
BACKGROUND: The body is dependent on the exogenous supply of omega 3 polyunsaturated fatty acids (n3 PUFA). These essential fatty acids are key players in regulating metabolic signaling but also exert anti inflammatory and anti carcinogenic properties. The liver is a major metabolic organ involved in fatty acid metabolism. Under experimental conditions n3 PUFA exert beneficial effect on hepatic steatosis regeneration and inflammatory insults such as ischemic injury after surgery. Some of these effects have also been observed in human subjects. However it is unclear whether perioperative administration of n3 PUFA is sufficient to protect the liver from ischemic injury. Therefore we designed a randomized controlled trial (RCT) assessing n3 PUFA (pre ) conditioning strategies in patients scheduled for liver surgery. METHODS/DESIGN: The Omegaven trial is a multi centric double blind randomized placebo controlled trial applying two single doses of Omegaven or placebo on 258 patients undergoing major liver resection. Primary endpoints are morbidity and mortality one month after hospital discharge defined by the Clavien Dindo classification of surgical complications (Ann Surg 240(2):205 13 2004) as well as the Comprehensive Complication Index (CCI) (Ann Surg 258(1):1 7 2013). Secondary outcome variables include length of Intensive Care Unit (ICU) and hospital stay postoperative liver function tests fatty acid and eicosanoid concentration inflammatory markers in serum and in liver tissue. An interim analysis is scheduled after the first 30 patients per randomization group. DISCUSSION: Long term administration of n3 PUFA have a beneficial effect on metabolism and hepatic injury. Patients often require surgery without much delay thus long term n3 PUFA uptake is not possible. Also lack of compliance may lead to incomplete n3 PUFA substitution. Hence perioperative Omegaven™ may provide an easy and controllable way to ensure hepaative application of tic protection. TRIAL REGISTRATION: ClinicalTrial.gov: ID: NCT01884948 registered June 14 2013; Institution Ethical Board Approval: KEK ZH Nr. 2010 0038; Swissmedic Notification: 2012DR3215
- Published
- 2015
- Full Text
- View/download PDF
24. The Involvement of Programmed Cell Death in the Phenotypic Expression of Ataxia telangiectasia
- Author
-
Humar, B., primary, M�ller, Hj., additional, and Scott, R. J., additional
- Full Text
- View/download PDF
25. P113 DEFICIENT MICRORNA-21 INDUCTION PROMOTES SMALL-FOR-SIZE SYNDROME FOLLOWING EXTENDED HEPATECTOMY IN MICE
- Author
-
Kachaylo, E., primary, Tschuor, C., additional, Limani, P., additional, Lehmann, K., additional, Ramadori, P., additional, Foti, M., additional, Graf, R., additional, Humar, B., additional, and Clavien, P.-A., additional
- Published
- 2014
- Full Text
- View/download PDF
26. THU-464 - Molecular Mechanisms Underlying the Unprecedented Liver Regeneration Induced by Alpps Surgery
- Author
-
Langiewicz, M., Schlegel, A., Humar, B., Graf, R., and Clavien, P.-A.
- Published
- 2016
- Full Text
- View/download PDF
27. Liver Graft Regeneration in a Rodent Model of Auxiliary Partial Liver Xenotransplantation
- Author
-
Tian, Y., primary, Fehr, T., additional, Weber, A., additional, Humar, B., additional, Graf, R., additional, and Clavien, P., additional
- Published
- 2012
- Full Text
- View/download PDF
28. Slow proliferation as a biological feature of colorectal cancer metastasis
- Author
-
Anjomshoaa, A, primary, Nasri, S, additional, Humar, B, additional, McCall, J L, additional, Chatterjee, A, additional, Yoon, H-S, additional, McNoe, L, additional, Black, M A, additional, and Reeve, A E, additional
- Published
- 2009
- Full Text
- View/download PDF
29. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
- Author
-
Graziano, F, primary, Ruzzo, A, additional, Canestrari, E, additional, Loupakis, F, additional, Santini, D, additional, Rulli, E, additional, Humar, B, additional, Galluccio, N, additional, Bisonni, R, additional, Floriani, I, additional, Maltese, P, additional, Falcone, A, additional, Tonini, G, additional, Catalano, V, additional, Fontana, A, additional, Giustini, L, additional, Masi, G, additional, Vincenzi, B, additional, Alessandroni, P, additional, and Magnani, M, additional
- Published
- 2008
- Full Text
- View/download PDF
30. Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer
- Author
-
Anjomshoaa, A, primary, Lin, Y-H, additional, Black, M A, additional, McCall, J L, additional, Humar, B, additional, Song, S, additional, Fukuzawa, R, additional, Yoon, H-S, additional, Holzmann, B, additional, Friederichs, J, additional, van Rij, A, additional, Thompson-Fawcett, M, additional, and Reeve, A E, additional
- Published
- 2008
- Full Text
- View/download PDF
31. Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer
- Author
-
Ramos-de la Medina, A., primary, More, H., additional, Medina-Franco, H., additional, Humar, B., additional, Gamboa, A., additional, Ortiz, L. J., additional, Donohue, J. H., additional, and Guilford, P., additional
- Published
- 2006
- Full Text
- View/download PDF
32. Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy
- Author
-
Graziano, F., primary, Arduini, F., additional, Ruzzo, A., additional, Bearzi, I., additional, Humar, B., additional, More, H., additional, Guilford, P., additional, Testa, E., additional, Catalano, V., additional, and Cascinu, S., additional
- Published
- 2004
- Full Text
- View/download PDF
33. Increased levels of E2F-1-dependent DNA binding activity after UV- or -irradiation
- Author
-
Hofferer, M., primary, Wirbelauer, C., additional, Humar, B., additional, and Krek, W., additional
- Published
- 1999
- Full Text
- View/download PDF
34. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
- Author
-
Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bisonni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, and Magnani M
- Published
- 2008
- Full Text
- View/download PDF
35. Elevated frequency of p53-independent apoptosis after irradiation increases levels of DNA breaks in ataxia telangiectasia lymphoblasts.
- Author
-
Humar, B., Muller, H., and Scott, R. J.
- Subjects
- *
ATAXIA telangiectasia , *RADIOTHERAPY , *P53 antioncogene , *THERAPEUTICS - Abstract
Abstract. Ataxia telangiectasia is a recessive genetic disease featuring cerebellar degeneration, developmental abnormalities, high cancer risk, immunodeficiency, and radiosensitivity. Increased levels of unrepaired DNA breaks have been observed in irradiated ataxia telangiectasia cells compared to normal cells but no specific DNA break rejoining rate deficiency has been defined. Alterations in radiation-induced p53-dependent apoptosis have been reported for ataxia telangiectasia cells. This study investigated the radiation response of ataxia telangiectasia lymphoblastoid cells using the comet assay and uncovered a new feature of this technique, namely its capacity to preferentially detect living cells. It is shown here that early after exposure to gamma -rays, ataxia telangiectasia lymphoblasts exhibit an elevated frequency of cells committed to die via apoptosis. The observed apoptosis, which is likely to be independent of p53, leads to a higher number of DNA breaks during the first 3 h post irradiation in ataxia telangiectasia cells, relative to controls. Apart from cells undergoing apoptosis, ataxia telangiectasia lymphoblasts have an identical capacity to rejoin radiation-induced DNA breaks as controls. Results suggest that p53-independent apoptosis may contribute to the radiosensitivity and the immune defects of ataxia telangiectasia patients. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
36. Increased levels of E2F-1-dependent DNA binding activity after UV- or gamma-irradiation.
- Author
-
Höfferer, M, Wirbelauer, C, Humar, B, and Krek, W
- Abstract
In mammalian cells, DNA damage induces robust changes in gene expression and these changes contribute to the proper execution of cellular responses to DNA damage, including DNA repair, cell cycle arrest and apoptosis. The transcription factor E2F-1 has been suggested to play a key role in the regulation of cell cycle-dependent gene expression and apoptosis. These activities depend on the ability of E2F-1 to form functionally active DNA binding complexes. Here we describe an assay that allows one to measure E2F-1 DNA binding activity in naive cells. We find that DNA damage, generated by UV- or gamma-irradiation, prompts increased production of E2F-1 DNA binding activity, which, at least in part, originates from alterations in E2F-1 protein levels. These findings represent an indication for a role of the transcription factor E2F-1 in the DNA damage response pathway.
- Published
- 1999
- Full Text
- View/download PDF
37. Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
- Author
-
Graziano, F., Ruzzo, A., Canestrari, E., Loupakis, F., Santini, D., Rulli, E., Humar, B., Galluccio, N., Bisonni, R., Floriani, I., Maltese, P., Alfredo Falcone, Tonini, G., Fontana, A., Giustini, L., GIANLUCA MASI, Vincenzi, B., Alessandroni, P., and Magnani, M.
38. Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer
- Author
-
Graziano, F., Ruzzo, A., Loupakis, F., Canestrari, E., Santini, D., Catalano, V., Bisonni, R., Torresi, U., Floriani, I., Schiavon, G., Andreoni, F., Maltese, P., Rulli, E., Humar, B., Alfredo Falcone, Giustini, L., Tonini, G., GIANLUCA MASI, Silva, R., and Magnani, M.
39. A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population.
- Author
-
Nasri S, More H, Graziano F, Ruzzo A, Wilson E, Dunbier A, McKinney C, Merriman T, Guilford P, Magnani M, Humar B, Nasri, Soroush, More, Helen, Graziano, Francesco, Ruzzo, Annamaria, Wilson, Emily, Dunbier, Anita, McKinney, Cushla, Merriman, Tony, and Guilford, Parry
- Abstract
Background: Inherited genetic factors such as E-cadherin (CDH1) promoter variants are believed to influence the risk towards sporadic diffuse gastric cancer (DGC). Recently, a new regulatory region essential for CDH1 transcription has been identified in CDH1 intron 2.Methods: We genotyped all known polymorphisms located within conserved sequences of CDH1 intron 2 (rs10673765, rs9932686, rs1125557, rs9282650, rs9931853) in an Italian population consisting of 134 DGC cases and 100 healthy controls (55 patient relatives and 45 unrelated, matched individuals). The influence of individual variants on DGC risk was assessed using chi2-tests and logistic regression. The relative contribution of alleles was estimated by haplotype analysis.Results: We observed a significant (p < 0.0004) association of the CDH1 163+37235G>A variant (rs1125557) with DGC risk. Odds ratios were 4.55 (95%CI = 2.09-9.93) and 1.38 (95%CI = 0.75-2.55) for AA and GA carriers, respectively. When adjusted for age, sex, smoking status, alcohol intake and H. pylori infection, the risk estimates remained largely significant for AA carriers. Haplotype analysis suggested the 163+37235A-allele contributes to disease risk independently of the other variants studied.Conclusion: The CDH1 163+37235G>A polymorphism may represent a novel susceptibility variant for sporadic DGC if confirmed in other populations. Considering the broad expression of E-cadherin in epithelia, this exploratory study encourages further evaluation of the 163+37235A-allele as a susceptibility variant in other carcinomas. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
40. NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo.
- Author
-
Namoto K, Baader C, Orsini V, Landshammer A, Breuer E, Dinh KT, Ungricht R, Pikiolek M, Laurent S, Lu B, Aebi A, Schönberger K, Vangrevelinghe E, Evrova O, Sun T, Annunziato S, Lachal J, Redmond E, Wang L, Wetzel K, Capodieci P, Turner J, Schutzius G, Unterreiner V, Trunzer M, Buschmann N, Behnke D, Machauer R, Scheufler C, Parker CN, Ferro M, Grevot A, Beyerbach A, Lu WY, Forbes SJ, Wagner J, Bouwmeester T, Liu J, Sohal B, Sahambi S, Greenbaum LE, Lohmann F, Hoppe P, Cong F, Sailer AW, Ruffner H, Glatthar R, Humar B, Clavien PA, Dill MT, George E, Maibaum J, Liberali P, and Tchorz JS
- Subjects
- Animals, Humans, Mice, Cell Proliferation, Stem Cells metabolism, Transcription Factors metabolism, Protein Serine-Threonine Kinases antagonists & inhibitors, Protein Serine-Threonine Kinases metabolism, YAP-Signaling Proteins agonists, YAP-Signaling Proteins drug effects, YAP-Signaling Proteins metabolism, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors pharmacology
- Abstract
The YAP/Hippo pathway is an organ growth and size regulation rheostat safeguarding multiple tissue stem cell compartments. LATS kinases phosphorylate and thereby inactivate YAP, thus representing a potential direct drug target for promoting tissue regeneration. Here, we report the identification and characterization of the selective small-molecule LATS kinase inhibitor NIBR-LTSi. NIBR-LTSi activates YAP signaling, shows good oral bioavailability, and expands organoids derived from several mouse and human tissues. In tissue stem cells, NIBR-LTSi promotes proliferation, maintains stemness, and blocks differentiation in vitro and in vivo. NIBR-LTSi accelerates liver regeneration following extended hepatectomy in mice. However, increased proliferation and cell dedifferentiation in multiple organs prevent prolonged systemic LATS inhibition, thus limiting potential therapeutic benefit. Together, we report a selective LATS kinase inhibitor agonizing YAP signaling and promoting tissue regeneration in vitro and in vivo, enabling future research on the regenerative potential of the YAP/Hippo pathway., Competing Interests: Declaration of interests All authors except C.B., E.B., K.T.D., W.-Y.L., S.J.F., B.H., M.T.D., P.-A.C., and P.L. are or were employees of Novartis Pharma AG., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Screening for mitochondrial function before use-routine liver assessment during hypothermic oxygenated perfusion impacts liver utilization.
- Author
-
Eden J, Breuer E, Birrer D, Müller M, Pfister M, Mayr H, Sun K, Widmer J, Huwyler F, Ungethüm U, Humar B, Gupta A, Schiess S, Wendt M, Immer F, Elmer A, Meierhofer D, Schlegel A, and Dutkowski P
- Subjects
- Humans, Perfusion methods, Liver, Tissue Donors, Graft Survival, Organ Preservation methods, Liver Transplantation adverse effects, Liver Transplantation methods
- Abstract
Background: To report on a concept of liver assessment during ex situ hypothermic oxygenated perfusion (HOPE) and its significant impact on liver utilization., Methods: An analysis of prospectively collected data on donation after circulatory death (DCD) livers, treated by HOPE at our institution, during a 11-year period between January 2012 and December 2022., Findings: Four hundred and fifteen DCD Maastricht III livers were offered during the study period in Switzerland, resulting in 249 liver transplants. Of those, we performed 158 DCD III liver transplants at our institution, with 1-year patient survival and death censored graft survival (death with functioning graft) of 87 and 89%, respectively, thus comparable to benchmark graft survivals of ideal DBD and DCD liver transplants (89% and 86%). Correspondingly, graft loss for primary non-function or cholangiopathy was overall low, i.e., 7/158 (4.4%) and 11/158 (6.9%), despite more than 82% of DCD liver grafts ranked high (6-10 points) or futile risk (>10 points) according to the UK-DCD score. Consistently, death censored graft survival was not different between low-, high-risk or futile DCD III livers. The key behind these achievements was the careful development and implementation of a routine perfusate assessment of mitochondrial biomarkers for injury and function, i.e., release of flavin mononucleotide from complex I, perfusate NADH, and mitochondrial CO
2 production during HOPE, allowing a more objective interpretation of liver quality on a subcellular level, compared to donor derived data., Interpretation: HOPE after cold storage is a highly suitable and easy to perform perfusion approach, which allows reliable liver graft assessment, enabling surgeons to make a fact based decision on whether or not to implant the organ. HOPE-treatment should be combined with viability assessment particularly when used for high-risk organs, including DCD livers or organs with relevant steatosis., Funding: This study was supported by the Swiss National Foundation (SNF) grant 320030_189055/1 to PD., Competing Interests: Declaration of interests A.S. received consultant fees for presentations from Bridge to life LTD, all other authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
42. Defatting of Human Livers During Long-Term e x situ Normothermic Perfusion: Novel Strategy to Rescue Discarded Organs for Transplantation.
- Author
-
Sousa Da Silva RX, Bautista Borrego L, Lenggenhager D, Huwyler F, Binz J, Mancina L, Breuer E, Wernlé K, Hefti M, Mueller M, Cunningham L, De Oliveira ML, Petrowsky H, Weber A, Dutkowski P, Hoffmann W, Gupta A, Tibbitt MW, Humar B, and Clavien PA
- Subjects
- Humans, Organ Preservation methods, Liver pathology, Perfusion methods, Fatty Liver, Liver Transplantation methods
- Abstract
Objective: To develop a protocol for the defatting of steatotic liver grafts during long-term ex situ normothermic machine perfusion., Background: Despite the alarming increase in donor organ shortage, the highly prevalent fatty liver grafts are often discarded due to the risk of primary nonfunction. Effective strategies preventing such outcomes are currently lacking. An exciting new avenue is the introduction of ex situ normothermic machine perfusion (NMP), enabling a liver to remain fully functional for up to 2 weeks and providing a unique window of opportunity for defatting before transplantation., Methods: Over a 5-year period, 23 discarded liver grafts and 28 partial livers from our resection program were tested during ex situ normothermic machine perfusion. The steatosis degree was determined on serial biopsies by expert pathologists, and triglyceride contents were measured simultaneously., Results: Of 51 liver grafts, 20 were steatotic, with up to 85% macrovesicular steatosis, and were perfused for up to 12 days. Ten livers displayed marked (5 of which almost complete) loss of fat, while the other 10 did not respond to long-term perfusion. Successful defatting was related to prolonged perfusion, automated glucose control, circadian nutrition, and L-carnitine/fenofibrate supplementation. Pseudopeliotic steatosis and the associated activation of Kupffer/stellate cells were unexpected processes that might contribute to defatting. Synthetic and metabolic functions remained preserved for most grafts until perfusion ended., Conclusion: Ex situ long-term perfusion effectively reduces steatosis while preserving organ viability and may in the future allow transplantation of primarily unusable high-risk grafts, significantly increasing the number of organs available for transplantation., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
43. Surgical Approach, Challenges, and Resolutions for Uterus Transplantation in Rats.
- Author
-
Sun K, Bochicchio D, Clavien PA, Dutkowski P, and Humar B
- Subjects
- Humans, Pregnancy, Rats, Female, Animals, Uterus transplantation, Models, Biological, Infertility, Female therapy, Organ Transplantation methods, Transplants
- Abstract
Uterine transplantation (UTx) is a new approach for treating women with absolute uterine factor infertility (AUFI). An estimated 3%-5% of women suffer from AUFI. These women were deprived of the option to have children until the advent of UTx. The clinical application of UTx was driven by experimental studies in animals, and the first successful UTx was achieved in rats. Given their physiological, immunological, genetic, and reproductive characteristics, rats are a suitable model system for such transplants. In particular, their short gestation period is a clear advantage, as the usual endpoint of experimental UTx is successful pregnancy with live birth. The biggest challenge for rat models remains the small anatomy, which requires advanced microsurgical skills and experience. Although UTx has led to pregnancy in the clinic, the procedure is not established and requires continuous experimental optimization. Here, a detailed protocol is presented, including essential troubleshooting for rat UTx, which is expected to make the entire procedure easier to grasp for those without experience in this type of microsurgery.
- Published
- 2023
- Full Text
- View/download PDF
44. Normalization of lipid oxidation defects arising from hypoxia early posthepatectomy prevents liver failure in mouse.
- Author
-
Birrer DL, Kachaylo E, Breuer E, Linecker M, Kron P, Ungethüm U, Hagedorn C, Steiner R, Kälin C, Borrego LB, Dufour JF, Foti M, Hornemann T, Clavien PA, and Humar B
- Subjects
- Mice, Animals, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha metabolism, Hepatectomy adverse effects, Liver Regeneration physiology, Hypoxia, Carnitine metabolism, Lipids, Liver surgery, Liver metabolism, Liver Failure surgery
- Abstract
Surgical liver failure (SLF) develops when a marginal amount of hepatic mass is left after surgery, such as following excessive resection. SLF is the commonest cause of death due to liver surgery; however, its etiology remains obscure. Using mouse models of standard hepatectomy (sHx) (68%, resulting in full regeneration) or extended hepatectomy (eHx) (86%/91%, causing SLF), we explored the causes of early SLF related to portal hyperafflux. Assessing the levels of HIF2A with or without oxygenating agent inositol trispyrophosphate (ITPP) indicated hypoxia early after eHx. Subsequently, lipid oxidation (PPARA/PGC1α) was downregulated and associated with persisting steatosis. Mild oxidation with low-dose ITPP reduced the levels of HIF2A, restored downstream PPARA/PGC1α expression along with lipid oxidation activities (LOAs), and normalized steatosis and other metabolic or regenerative SLF deficiencies. Promotion of LOA with L-carnitine likewise normalized the SLF phenotype, and both ITPP and L-carnitine markedly raised survival in lethal SLF. In patients who underwent hepatectomy, pronounced increases in serum carnitine levels (reflecting LOA) were associated with better recovery. Lipid oxidation thus provides a link between the hyperafflux of O
2 -poor portal blood, the metabolic/regenerative deficits, and the increased mortality typifying SLF. Stimulation of lipid oxidation-the prime regenerative energy source-particularly through L-carnitine may offer a safe and feasible way to reduce SLF risks in the clinic., (Copyright © 2022 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
45. Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice.
- Author
-
Breuer E and Humar B
- Subjects
- Mice, Male, Animals, Mice, Inbred C57BL, Liver Regeneration, Hepatocytes, Liver, Hepatectomy methods, Fatty Liver surgery
- Abstract
Partial hepatectomy has been widely used to investigate liver regeneration in mice, but the isolation of high yields of viable hepatocytes for downstream single-cell applications is challenging. A marked accumulation of lipids within regenerating hepatocytes is observed during the first 2 days of normal liver regeneration in mice. This so-called transient regeneration-associated steatosis (TRAS) is temporary but partially overlaps the major proliferative phase. Density-gradient purification is the backbone of most existing protocols for the isolation of primary hepatocytes. As gradient purification relies on the density and size of cells, it separates non-steatotic from steatotic hepatocyte populations. Therefore, fatty hepatocytes often are lost, yielding non-representative hepatocyte fractions. The presented protocol describes an easy and reliable method for the in vivo isolation of regenerating hepatocytes regardless of their lipid content. Hepatocytes from male C57BL/6 mice are isolated 24-48 h after hepatectomy by a classic two-step collagenase perfusion approach. A standard peristaltic pump drives the warmed solutions via the catheterized inferior vena cava into the remnant, using a retrograde perfusion technique with outflow through the portal vein. Hepatocytes are dissociated by collagenase for their release from the Glisson's capsule. After washing and careful centrifugation, the hepatocytes can be used for any downstream analyses. In conclusion, this paper describes a straightforward and reproducible technique for the isolation of a representative population of regenerating hepatocytes after partial hepatectomy in mice. The method may also aid the study of fatty liver disease.
- Published
- 2022
- Full Text
- View/download PDF
46. Sex Disparities in Outcomes Following Major Liver Surgery: New Powers of Estrogen?
- Author
-
Birrer DL, Linecker M, López-López V, Brusadin R, Navarro-Barrios Á, Reese T, Arbabzadah S, Balci D, Malago M, Machado MA, Ardiles V, Soubrane O, Hernandez-Alejandro R, de Santibañes E, Oldhafer KJ, Popescu I, Humar B, Clavien PA, and Robles-Campos R
- Subjects
- Animals, Estrogens, Female, Hepatectomy, Humans, Ligation, Liver surgery, Liver Regeneration, Male, Mice, Portal Vein surgery, Severity of Illness Index, Treatment Outcome, End Stage Liver Disease surgery, Liver Neoplasms surgery
- Abstract
Aim: To explore potential sex differences in outcomes and regenerative parameters post major hepatectomies., Background: Although controversial, sex differences in liver regeneration have been reported for animals. Whether sex disparity exists in human liver regeneration is unknown., Methods: Data from consecutive hepatectomy patients (55 females, 67 males) and from the international ALPPS (Associating-Liver-Partition-and-Portal-vein-ligation-for-Staged-hepatectomy, a two stage hepatectomy) registry (449 females, 729 males) were analyzed. Endpoints were severe morbidity (≥3b Clavien-Dindo grades), Model for End-stage Liver Disease (MELD) scores, and ALPPS interstage intervals. For validation and mechanistic insight, female-male ALPSS mouse models were established. t , χ 2 , or Mann-Whitney tests were used for comparisons. Univariate/multivariate analyses were performed with sensitivity inclusion., Results: Following major hepatectomy (Hx), males had more severe complications ( P =0.03) and higher liver dysfunction (MELD) P =0.0001) than females. Multivariate analysis established male sex as a predictor of complications after ALPPS stage 1 (odds ratio=1.78; 95% confidence interval: 1.126-2.89; P =0.01), and of enhanced liver dysfunction after stage 2 (odds ratio=1.93; 95% confidence interval: 1.01-3.69; P =0.045). Female patients displayed shorter interstage intervals (<2 weeks, 64% females versus 56% males, P =0.01), however, not in postmenopausal subgroups. In mice, females regenerated faster than males after ALPPS stage 1, an effect that was lost upon estrogen antagonism., Conclusions: Poorer outcomes after major surgery in males and shorter ALPPS interstage intervals in females not necessarily suggest a superior regenerative capacity of female liver. The loss of interstage advantages in postmenopausal women and the mouse experiments point to estrogen as the driver behind these sex disparities. Estrogen's benefits call for an assessment in postmenopausal women, and perhaps men, undergoing major liver surgery., Competing Interests: The authors report no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Integral analysis of hydrodynamic cavitation effects on waste activated sludge characteristics, potentially toxic metals, microorganisms and identification of microplastics.
- Author
-
Repinc SK, Bizjan B, Budhiraja V, Dular M, Gostiša J, Brajer Humar B, Kaurin A, Kržan A, Levstek M, Arteaga JFM, Petkovšek M, Rak G, Stres B, Širok B, Žagar E, and Zupanc M
- Subjects
- Anaerobiosis, Humans, Hydrodynamics, Plastics, Waste Disposal, Fluid, Wastewater, Microplastics, Sewage
- Abstract
Wastewater treatment plants, the last barrier between ever-increasing human activities and the environment, produce huge amounts, of unwanted semi-solid by-product - waste activated sludge. Anaerobic digestion can be used to reduce the amount of sludge. However, the process needs extensive modernisation and refinement to realize its full potential. This can be achieved by using efficient pre-treatment processes that result in high sludge disintegration and solubilization. To this end, we investigated the efficiency of a novel pinned disc rotational generator of hydrodynamic cavitation. The results of physical and chemical evaluation showed a reduction in mean particle size up to 88%, an increase in specific surface area up to 300% and an increase in soluble COD, NH
4 -N, NO3 -N, PO4 -P up to 155.8, 126.3, 250 and 29.7%, respectively. Microscopic images confirmed flocs disruption and damage to yeast cells and Epistilys species due to mechanical effects of cavitation such as microjets and shear forces. The observed cell ruptures and cracks were sufficient for the release of small soluble biologically relevant dissolved organic molecules into the bulk liquid, but not for the release of microbial DNA. Cavitation treatment also decreased total Pb concentrations by 70%, which was attributed to the reactions triggered by the chemical effects of cavitation. Additionally, the study confirmed the presence of microplastic particles and fibers of polyethylene, polyethylene terephthalate, polypropylene, and nylon 6 in the waste activated sludge., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
48. Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis.
- Author
-
Correia de Sousa M, Calo N, Sobolewski C, Gjorgjieva M, Clément S, Maeder C, Dolicka D, Fournier M, Vinet L, Montet X, Dufour JF, Humar B, Negro F, Sempoux C, and Foti M
- Abstract
The microRNA 21 (miR-21) is upregulated in almost all known human cancers and is considered a highly potent oncogene and potential therapeutic target for cancer treatment. In the liver, miR-21 was reported to promote hepatic steatosis and inflammation, but whether miR-21 also drives hepatocarcinogenesis remains poorly investigated in vivo. Here we show using both carcinogen (Diethylnitrosamine, DEN) or genetically (PTEN deficiency)-induced mouse models of hepatocellular carcinoma (HCC), total or hepatocyte-specific genetic deletion of this microRNA fosters HCC development-contrasting the expected oncogenic role of miR-21. Gene and protein expression analyses of mouse liver tissues further indicate that total or hepatocyte-specific miR-21 deficiency is associated with an increased expression of oncogenes such as Cdc25a , subtle deregulations of the MAPK, HiPPO, and STAT3 signaling pathways, as well as alterations of the inflammatory/immune anti-tumoral responses in the liver. Together, our data show that miR-21 deficiency promotes a pro-tumoral microenvironment, which over time fosters HCC development via pleiotropic and complex mechanisms. These results question the current dogma of miR-21 being a potent oncomiR in the liver and call for cautiousness when considering miR-21 inhibition for therapeutic purposes in HCC.
- Published
- 2021
- Full Text
- View/download PDF
49. Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
- Author
-
Schneider MA, Linecker M, Fritsch R, Muehlematter UJ, Stocker D, Pestalozzi B, Samaras P, Jetter A, Kron P, Petrowsky H, Nicolau C, Lehn JM, Humar B, Graf R, Clavien PA, and Limani P
- Subjects
- Administration, Intravenous, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor blood, Colorectal Neoplasms drug therapy, Colorectal Neoplasms pathology, Digestive System Neoplasms pathology, Female, Humans, Inositol Phosphates pharmacokinetics, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Male, Middle Aged, Progression-Free Survival, Digestive System Neoplasms drug therapy, Hypoxia drug therapy, Inositol Phosphates therapeutic use
- Abstract
Hypoxia is prominent in solid tumors and a recognized driver of malignancy. Thus far, targeting tumor hypoxia has remained unsuccessful. Myo-inositol trispyrophosphate (ITPP) is a re-oxygenating compound without apparent toxicity. In preclinical models, ITPP potentiates the efficacy of subsequent chemotherapy through vascular normalization. Here, we report the results of an unrandomized, open-labeled, 3 + 3 dose-escalation phase Ib study (NCT02528526) including 28 patients with advanced primary hepatopancreatobiliary malignancies and liver metastases of colorectal cancer receiving nine 8h-infusions of ITPP over three weeks across eight dose levels (1'866-14'500 mg/m
2 /dose), followed by standard chemotherapy. Primary objectives are assessment of the safety and tolerability and establishment of the maximum tolerated dose, while secondary objectives include assessment of pharmacokinetics, antitumor activity via radiological evaluation and assessment of circulatory tumor-specific and angiogenic markers. The maximum tolerated dose is 12,390 mg/m2 , and ITPP treatment results in 32 treatment-related toxicities (mostly hypercalcemia) that require little or no intervention. 52% of patients have morphological disease stabilization under ITPP monotherapy. Following subsequent chemotherapy, 10% show partial responses while 60% have stable disease. Decreases in angiogenic markers are noted in ∼60% of patients after ITPP and tend to correlate with responses and survival after chemotherapy.- Published
- 2021
- Full Text
- View/download PDF
50. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
- Author
-
Sobolewski C, Abegg D, Berthou F, Dolicka D, Calo N, Sempoux C, Fournier M, Maeder C, Ay AS, Clavien PA, Humar B, Dufour JF, Adibekian A, and Foti M
- Subjects
- Animals, Biomarkers, Tumor immunology, Biomarkers, Tumor metabolism, Cell Line, Disease Progression, Drug Discovery, Gene Expression Profiling methods, Humans, Inflammation metabolism, Liver immunology, Liver pathology, Mice, Obesity immunology, Prognosis, Carcinogenesis immunology, Carcinogenesis metabolism, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular pathology, Fatty Liver immunology, Fatty Liver pathology, Liver Neoplasms immunology, Liver Neoplasms pathology, S100 Proteins immunology, S100 Proteins metabolism
- Abstract
Objective: Hepatocellular carcinoma (HCC) development occurs with non-alcoholic fatty liver disease (NAFLD) in the absence of cirrhosis and with an increasing incidence due to the obesity pandemic. Mutations of tumour suppressor (TS) genes and oncogenes (ONC) have been widely characterised in HCC. However, mounting evidence indicates that non-genomic alterations of TS/ONC occur early with NAFLD, thereby potentially promoting hepatocarcinogenesis in an inflammatory/fibrotic context. The aim of this study was to identify and characterise these alterations., Design: The proteome of steatotic liver tissues from mice spontaneously developing HCC was analysed. Alterations of TSs/ONCs were further investigated in various mouse models of NAFLD/HCC and in human samples. The inflammatory, fibrogenic and oncogenic functions of S100A11 were assessed through in vivo, in vitro and ex-vivo analyses., Results: A whole set of TSs/ONCs, respectively, downregulated or upregulated was uncovered in mice and human with NAFLD. Alterations of these TSs/ONCs were preserved or even exacerbated in HCC. Among them, overexpression of S100A11 was associated with high-grade HCC and poor prognosis. S100A11 downregulation in vivo significantly restrains the development of inflammation and fibrosis in mice fed a choline/methionine-deficient diet. Finally, in vitro and ex-vivo analyses revealed that S100A11 is a marker of hepatocyte de-differentiation, secreted by cancer cells, and promoting cell proliferation and migration., Conclusion: Cellular stress associated with NAFLD triggers non-genomic alterations of a whole network of TSs/ONCs fostering hepatocarcinogenesis. Among those, overexpression of the oncogenic factor S100A11 promotes inflammation/fibrosis in vivo and is significantly associated with high-grade HCC with poor prognosis., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.